+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Novel oral anticoagulants in the treatment of cerebral venous thrombosis

Novel oral anticoagulants in the treatment of cerebral venous thrombosis

International Angiology 35(4): 365-368

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation. The aim of our work was to review the available evidence for NOACs in the treatment of CVT. Based on our literature search there is insufficient evidence to support the use of NOACs in CVT, although case series with rivaroxaban and dabigatran have showed promising results.

(PDF emailed within 1 workday: $29.90)

Accession: 058433478

Download citation: RISBibTeXText

PMID: 25994451

Related references

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. Systematic Reviews 8(1): 99, 2019

Cerebral venous and sinus thrombosis treatment with anticoagulants. Der Nervenarzt 52(4): 243-246, 1981

Home treatment of deep venous thrombosis in the era of new oral anticoagulants. Clinical and Applied Thrombosis/Hemostasis 21(8): 729-732, 2016

Off-label use of novel anticoagulants for treatment of cerebral venous thrombosis: A Canadian survey. International Journal of Stroke 12(9): Np16-Np18, 2016

Direct oral anticoagulants in patients with cervical artery dissection and cerebral venous thrombosis. A case series and review of the literature. International Journal of Cardiology 244: 282-284, 2017

Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klinische Wochenschrift 56(16): 801-804, 1978

Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase. International Heart Journal 59(1): 126-135, 2017

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery 33(1): 77-90, 2001

Is the evidence limited for the exchangeability of new oral anticoagulants and warfarin for the treatment of symptomatic venous thrombosis or pulmonary embolism?. Australian Family Physician 43(8): 504-505, 2015

Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet 351(9113): 1404, 1998

Anticoagulants and cerebral venous thrombosis. Australian and New Zealand Journal of Medicine 14(5): 643-648, 1984

Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation. Canadian Journal of Hospital Pharmacy 70(3): 188-199, 2017

Cerebral venous thrombosis: anticoagulants or thrombolyic therapy?. Journal of Neurology, Neurosurgery, and Psychiatry 69(4): 427-430, 2000

Anticoagulants for cerebral venous thrombosis: harmful to patients?. Stroke 45(1): 298-304, 2014

Direct oral anticoagulants in rare venous thrombosis. Internal and Emergency Medicine 11(2): 167-170, 2017